Pharmacokinetics of Meropenem in Burn Patients with Infections Caused by Gram Negative Bacteria: Are We Getting Close to the Right Treatment? by Corcione, Silvia et al.
Journal of Global Antimicrobial Resistance 20 (2020) 22–27Pharmacokinetics of meropenem in burn patients with infections
caused by Gram-negative bacteria: Are we getting close to the right
treatment?
Silvia Corcionea,*, Antonio D’Avoliob, Riccardo Corgiat Loiaa, Anna Pensac,
Francesco Vladimiro Segalaa, Amedeo De Nicolòb, Giovanna Fatigusob,
Mariarosa Romeoc, Giovanni Di Perria, Maurizio Stellac, Francesco Giuseppe De Rosaa
aDepartment of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy
bDepartment of Medical Sciences, University of Turin–ASL ‘Città di Torino’, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia
Hospital, Turin, Italy
cBurn Center, CTO Hospital, Città della Salute e della Scienza, Turin, Italy
A R T I C L E I N F O
Article history:
Received 3 October 2018
Received in revised form 4 June 2019
Accepted 10 June 2019
Available online 14 June 2019
Keywords:
Burn
Meropenem
Pharmacokinetics
Pharmacodynamics
Multidrug-resistant
Infection
A B S T R A C T
Objectives: Infections caused by multidrug-resistant Gram-negative bacteria are associated with high
mortality. A relevant concern is the efficacy of antibiotic therapy in burn patients in whom
pathophysiological changes strongly influence pharmacokinetic (PK) parameters. This study aimed to
describe the PK parameters of meropenem in a population of burn patients.
Methods: Blood samples were collected immediately before and 2 h and 5 h after the start of intravenous
drug administration. Plasma meropenem concentrations were determined using an ultra-performance
liquid chromatography–photodiode array method.
Results: Seventeen burn patients were enrolled in the study. Thirteen patients (76%) were treated with
meropenem for infections byPseudomonas aeruginosa or Acinetobacter baumannii isolated from blood or
wounds. Mean Cmax, Cmin, AUC0–24, half-life, drug clearance and volume of distribution were 28.9 mg/L,
3.7 mg/L, 280.2 mg h/L, 2.0 h, 19.0 L/h and 44.4 L, respectively. Six patients (35%) achieved a Cmin3.3 mg/
L and seven patients (41%) achieved a Cmax 28.4 mg/L, whilst nine patients (53%) achieved an AUC0–24 of
>226 mg h/L. Given a minimum inhibitory concentration (MIC) of 0.5 mg/L, all patients satisfied the
target AUC/MIC of >125, but when the MIC rises to 2 mg/L (the ECOFF), only five patients reached the
desired AUC/MIC. Regarding fT>MIC at an MIC of 2 mg/L with a 2-h infusion time, 13 patients (76%)
achieved the PK target (>75%).
Conclusion: These data suggest that a combined 2-h infusion with a higher dosage of meropenem,
including a loading dose, may be successful to achieve effective PK parameters.
© 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. All rights
reserved.
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Despite improvements in the early care of burn patients,
infections remain one of the major causes of mortality, responsible
for 46–51% of multiorgan failure triggers [1]. In recent years, the
emergence of infections caused by multidrug-resistant (MDR)
Gram-negative bacteria, such as Pseudomonas aeruginosa, Acine-
tobacter baumannii and Klebsiella pneumoniae, represents a global* Corresponding author.
E-mail address: corcione.silvia@gmail.com (S. Corcione).
https://doi.org/10.1016/j.jgar.2019.06.011
2213-7165/© 2019 International Society for Antimicrobial Chemotherapy. Published bythreat, also in the setting of burn patients [1]. Along with the high
mortality rate associated with these infections, an important
concern is the efficacy of antibiotic treatment, especially for burn
patients in whom pathophysiological changes strongly influence
the pharmacokinetic (PK) parameters of many antibiotics [1–5].
Physiological changes in burn patients are time-dependent and
a number of factors, such as the area and depth of the burn,
presence of sepsis, degree of hydration, serum protein concen-
trations, age, creatinine clearance and time after injury, may affect
pharmacokinetics in burn patients [1–5]. In fact, major changes in
fluid volume may increase the volume of distribution of a drug
thereby lowering its concentration when a standard dose is given. Elsevier Ltd. All rights reserved.
Table 1
Clinical and pharmacokinetic parameters of burn patients treated with meropenem.
Pt. ID Age
(years)
Sex BMI Degree
of burn
%
TBSA
RBS CCI Reconstructive
operations (n)
MELD
score
CLCr
(mL/
min)
CRRT MV Septic
shock
Possible
drug–drug
interactions
In-hospital
mortality
Cmax
(mg/L)
Cmin
(mg/L)
AUCss
(mg h/L)
AUC0–24
(mg h/L)
t1/2
(h)
CLss
(L/h)
Vd
(L)
Dose
1 71 M 29 2 50 143 5 Y (1) 8 86 N Y N None N 14.3 2.4 91.3 182.6 3.8 10.9 60.3 1 g b.
i.d.
2 40 M 22 2 40 97 0 Y (3) 9 247 N N N None N 11.3 0.0 25.7 77.1 0.4 38.9 25.0 1 g t.
i.d.
3 25 M 22 2 50 92 0 Y (5) 12 252 N Y N None N 17.1 3.1 61.7 185.1 2.4 32.4 112.9 2 g t.
i.d.
4 43 M 29 2 55 115 0 Y (5) 15 64 Y Y Y Norepinephrine N 16.9 3.3 45.3 181.2 1.9 35.6 70.2 1 g q.
i.d.
5 25 M 23 2 50 92 0 Y (4) 10 277 N N N None N 29.2 0.7 78.1 234.3 1.1 25.6 41.3 2 g t.
i.d.
6 71 F 22 1 10 81 3 N 9 58 N N N None N 25.1 1.7 78.9 236.7 1.5 12.6 28.3 1 g t.
i.d.
7 81 M 27 2 40 138 4 Y (5) 10 211 N N Y Furosemide and
norepinephrine
N 31.1 0.8 81.2 243.6 1.1 24.6 41.0 2 g t.
i.d.
8 50 M 24 2 35 102 1 Y (1) 9 167 N N N None N 15.1 1.1 50.0 150 1.5 19.9 45.8 1 g t.
i.d.
9 72 M 25 2 15 87 3 Y (1) 9 85 N N N None N 35.6 0.0 75.8 227.4 0.3 13.1 7.5 1 g t.
i.d.
10 67 M 25 2 30 114 2 Y (6) 9 169 N Y N None N 20.8 3.6 67.5 202.5 2.3 14.8 50.5 1 g t.
i.d.
11 52 F 37 2 50 119 5 Y (4) 9 98 N Y N Furosemide and
norepinephrine
Y 26.0 8.4 121.7 365.1 3.7 8.2 43.8 1 g t.
i.d.
12 75 M 17 2 5 80 4 Y (2) 7 64 N Y N None N 36.5 6.7 158.3 474.9 2.4 6.3 22.4 1 g t.
i.d.
13 48 F 19 2 18 66 0 Y (2) 8 82 N N N None N 74.7 0.0 151.0 453 0.3 6.6 10.4 1 g t.
i.d.
14 40 F 23 2 35 75 0 Y (1) 11 150 N N N Furosemide N 16.0 0.6 36.0 108 1.2 27.7 20.1 1 g t.
i.d.
15 70 M 27 2 35 122 5 Y (1) 9 76 N Y Y Furosemide and
norepinephrine
Y 50.2 21.4 262.1 786.3 4.8 7.6 53.6 1 g t.
i.d.
16 64 M 27 2 45 127 2 Y (2) 20 31.7 N Y N Furosemide N 52.0 6.9 230.1 460.2 3.3 6.7 33.2 1 g b.
i.d.
17 80 M 30 1 10 107 7 Y (1) 8 157 N Y N Furosemide N 19.9 2.5 64.9 194.7 1.9 30.8 88.2 2 g t.
i.d.
Pt., patient; M,male; F, female; BMI, bodymass index; TBSA, total body surface area; RBS, revised Baux score; CCI, Charlson comorbidity index; Y, yes; N, no;MELD,Model for End-Stage Liver Disease; CLCr, creatinine clearance; CRRT,
continuous renal replacement therapy; MV, mechanical ventilation; Cmax, peak serum concentration; Cmin, trough serum concentration; AUCss, area under the concentration–time curve at steady-state; AUC0–24, area under the
concentration–time curve from 0–24 h; t1/2, half-life; CLss, drug clearance at steady-state; Vd, volume of distribution; b.i.d., twice daily; t.i.d., three times a day; q.i.d., four times a day.
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24 S. Corcione et al. / Journal of Global Antimicrobial Resistance 20 (2020) 22–27In addition, augmented renal blood flow in burn patients owing to
the increase in cardiac output may result in higher drug clearance
and a shorter elimination half-life [6,7].
Altered PK parameters may be responsible for toxic effects as
well as resulting in suboptimal antibiotic concentrations below
those required to be effective against MDR pathogens [2,4].Fig. 1. Mean drug concentration–time curves corresponding to dosages of (A) 2 g q8h, (B
q8h, every 8 h; q12 h, every 12 h.Subtherapeutic antibiotic concentrations may lead to antimi-
crobial resistance, which threatens the management of bacterial
infections in critically ill patients. Moreover, escalating antimicro-
bial resistance has substantially increased overall healthcare costs
as a result of prolonged hospitalisation associated with treatment
failures and the need for implementation of broader infection) 1 g q8h and (C) 1 g q12 h. Bars indicate the confidence intervals for the mean value.
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S. Corcione et al. / Journal of Global Antimicrobial Resistance 20 (2020) 22–27 25control interventions aimed at reducing the spread of antibiotic-
resistant pathogens [1–5].
Therefore, PK studies are necessary to produce accurate
recommendations that can be used as an additional tool in the
management of infections [8].
So far, few data are available regarding the pharmacokinetic/
pharmacodynamic (PK/PD) meropenem target for efficacy, espe-
cially in burn patients. Data from intensive care unit patients
described an area under the concentration–time curve from 0–24 h
(AUC0–24), trough serum concentration (Cmin) and peak serum
concentration (Cmax) of 226 mg h/L, 3.3 mg/L and 28.4 mg/L
respectively, as PK/PD targets [3,6,9–14].
Moreover, published data have described an AUC0–24/MIC
(minimum inhibitory concentration) ratio and %fT>MIC (percentage
of time that the drug concentration remains above the MIC) of 125
and 75%, respectively, as the most significant parameters to
evaluate the therapeutic efficacy of meropenem [3,6,9–14].
The aim of this prospective study was to describe the PK/PD
parameters of meropenem in burnpatients treated with a 2-h infusion.
2. Materials and methods
All patients admitted to the Burn Center of CTO Hospital, Città
della Salute e della Scienza (Turin, Italy) from January 2016 to April
2018 and treated with meropenem as empirical or targeted
therapy were prospectively enrolled in the study. Meropenem was
administered as a 2-h intravenous (i.v.) infusion at a dosage of 1 g
every 8 h (q8h) up to 2 g q8h according to the clinical character-
istics of the patient.
The study was approved by the local Ethical Committee of AOU
Città della Salute e della Scienza, and written informed consent
was obtained from patients before sampling. The study was
performed in accordance with International Conference on
Harmonisation Good Clinical Practice (ICH-GCP) guidelines and
the Declaration of Helsinki.
2.1. Patient characteristics
Information regarding demographic and clinical characteristics
was collected for each patient, including days of hospitalisation,
length of stay in the unit and specific burn index.
Sepsis and septic shock were classified according to the Third
International Consensus Definitions for Sepsis and Septic Shock
(Sepsis-3) [15]. Mortality was evaluated at discharge.
Microbiological data were also collected when available. In case
of targeted therapy, for each patient the micro-organism, site of
infection and MIC were reported.
2.2. Blood sampling and meropenem assay
Plasma meropenem concentrations were determined at steady-
state 48 h after the beginning of therapy. The Cmin corresponds to
concentration before administration and the Cmax is defined as the
concentration at the end of the infusion. The AUC0–24 of
meropenem was calculated with blood sample collection by
multiplying the AUC values corresponding to each daily dose (e.g.
AUC0–8 3) [10,13].
Blood samples were collected before the infusion, at the end of
the infusion (2 h) and 5 h after i.v. drug administration. Blood
samples were collected in lithium heparin tubes (7 mL) and plasma
was obtained by centrifugation at 2800  g for 10 min at 4 C (ALC
PK 130R refrigerated centrifuge; DJB Labcare Ltd., Newport Pagnell,
UK).
Each sample was stored at 20 C until analysis (<3 weeks).
Stability tests performed during method validation reported drug
stability (<5% degradation) within 1 month (data not shown).
26 S. Corcione et al. / Journal of Global Antimicrobial Resistance 20 (2020) 22–27Meropenem quantification was performed by an ultra-perfor-
mance liquid chromatography–photodiode array (UPLC-PDA)
method, validated following US Food and Drug Administration
(FDA) and European Medicines Agency (EMA) guidelines. Briefly,
200 mL of plasma was added to 50 mL of internal standard
(thymidine) and underwent protein precipitation with 400 mL of
acetonitrile:methanol (50:50 v:v) and then was diluted 1:10 with
pure water before injection on a ACQUITY UPLC HSS T3 column
(2.1 150 mm, 1.8 mm) (Waters Corp., Milford, MA, USA). Chro-
matographic separation was achieved in a gradient run of 10 mM
KH2PO4 (pH 3.2) and acetonitrile for 13 min at 40 C with a flow of
0.4 mL/min.
Accuracy as well as intraday and interday precision were all
within the limits imposed by the FDA and EMA guidelines
(deviations from nominal concentration and coefficients of
variation both <15%). Calibration curves were linear in the range
of 0.585–15 mg/L, with R2> 0.996 for each analytical session.
Samples with plasma concentrations >15 mg/L were diluted in
order to fit the linearity range, demonstrating good dilution
integrity after serial dilutions.
All PK parameters were calculated by means of a non-
compartmental model using Kinetica software (Thermo Fisher
Scientific, Waltham, MA, USA) and are summarised in Table 1 and
represented graphically in Fig. 1.
Simulated data for meropenem PK parameters calculated with
MICs corresponding to 0.5, 1 and 2 mg/L [susceptible by
epidemiological cut-off value (ECOFF)], 8 mg/L (resistant by ECOFF)
and 12 mg/L (6  ECOFF MIC) were calculated by considering a log-
linear elimination kinetic in accordance with the experimentally
determined half-life (t1/2) (Table 2).
Differences between different drug dosages (1 g vs. 2 g three
times a day) in terms of AUC or Cmin were through a non-
parametric Mann–Whitney test using IBM SPSS Statistics v.24.0
(IBM Corp., Armonk, NY, USA). Statistical comparisons for patients
treated with 1 g every 12 h or 1 g every 6 h were not performed
considering the small sample size (two and one patients,
respectively).
3. Results
Seventeen patients were enrolled in the study. All patients were
aged >25 years and had severe injuries [second- or third-degree
thermal injuries ranging from 5–55% of their total body surface
area (TBSA)] (Table 1).
The majority of patients were male (13/17; 76%), with a
mean  standard deviation (S.D.) age of 57  18.3 years, a
mean  S.D. TBSA of 34  16.4%, a mean  S.D. body mass index
(BMI) of 25.2  4.7, a mean serum creatinine concentration of
0.85 mg/dL and a mean creatinine clearance of 134 mL/min. The
mean total protein serum concentration was 5.8 g/dL (Table 1).
Most patients were receiving mechanical ventilation (9/17;
53%) and had an indwelling central arterial line (14/17; 82%) at the
time of infection (Table 1).
Thirteen patients (76%) were treated with meropenem as
targeted therapy for infections caused by MDR P. aeruginosa or A.
baumannii isolated from blood or wounds. According to the Sepsis-
3 criteria [15], 12 patients (71%) had sepsis and 3 (18%) had septic
shock. There were no deaths at 14 days from hospital admission,
whilst mortality at discharge was 12% (2/17) with a mean revised
Baux score [16,17] of 103. The main meropenem PK parameters are
reported in Table 1 and the AUC values are presented in Fig. 1. The
mean Cmax, Cmin, AUC0–24, t1/2, drug clearance and volume of
distribution (Vd) were 28.9 mg/L, 3.7 mg/L, 280.2 mg h/L, 2.0 h,
19.0 L/h and 44.4 L, respectively.
Six patients (35%) achieved a Cmin 3.3 mg/L and seven patients
(41%) achieved a Cmax> 28.4 mg/L, whilst nine patients (53%)achieved an AUC0–24 of >226 mg h/L. No statistically significant
differences in PK parameters were observed between different
dosing regimens (P-values of 0.787 for AUC, 0.324 for Cmax and
0.510 for Cmin).
Simulated data for meropenem PK parameters calculated with
MICs corresponding to 0.5, 1, 2 (ECOFF), 8 and 12 mg/L (6  ECODD
MIC) are reported in Table 2.
Given an MIC of 0.5 mg/L, all patients satisfied the target AUC/
MIC of >125, but when the MIC rose to 2 mg/L (ECOFF), only five
patients reached the desired AUC/MIC. Regarding fT>MIC at an MIC
of 2 mg/L with a prolonged infusion time of 2 h, 13 patients (76%)
achieved the pharmacokinetic target (>75%).
4. Discussion
Severe infections are the main cause of death among burn
victims, mainly due to loss of the natural skin barrier against
pathogenic micro-organisms. Moreover, coagulated proteins and
other microbial nutrients in the lesion as well as local avascular-
isation lead to bacterial colonisation and facilitate access to the
systemic circulation [3].
Antibiotic therapies are usually difficult to manage in this
setting, since patients with major burns experience pathological
changes that have been shown to influence the pharmacokinetics
of antibiotics. Subsequently, it has been demonstrated that
conventional doses of some antibiotics given to patients with
major burns may result in subtherapeutic serum concentrations
with unsuccessful microbiological and clinical cure [1–4].
Moreover, the increasing incidence of infections caused by MDR
Gram-negative infections in this setting poses a great challenge for
clinicians aiming to provide maximally effective therapy.
Here we report the main PK/PD findings of a 2-h infusion of
meropenem in burn patients aimed at identifying the best
treatment option in this setting. The patients included in this
study had a mean revised Baux score of 103, indicating that in this
group the expected mortality ranges from 30–55% depending on
age, burn extension and concomitant inhalation injury; noticeably,
observed mortality at hospital discharge was 12%.
The results showed wide PK variability among patients, as
already highlighted in previous studies on similar populations of
critical patients owing to the peculiar pathophysiological con-
ditions [6,18]. Deepening this issue, in terms of dosage or timing,
dosing regimens were adjusted on the basis of patient character-
istics (i.e. renal insufficiency, dialysis, renal replacement therapy,
fluid overload, degree of burns), leading to satisfactory PK coverage
throughout 24 h. This was further confirmed by the absence of
significant differences in terms of drug concentrations between
different dosing regimens (Fig. 1).
The mean Cmin and Cmax values were found to be similar to those
reported in the literature in 65% and 59% of patients, respectively
[3,6,9–14]. Of note, for TBSA  50%, only two patients had a
Cmin 3.3 mg/L and only one patient had a Cmax> 28.4 mg/L,
suggesting that the percentage TBSA might strongly affect the Vd
and other physiological parameters, although in the current study
no statistically significant correlation was found, possibly due to
the small number of patients enrolled.
Despite the 2-h i.v. infusion, patients in this study had lower
AUC0–24 compared with data from the literature, and only nine
patients (53%) achieved the target of >226 mg h/L [3,6,9–14].
Moreover, an AUC/MIC of 125 was achieved in all patients except
one when the MIC was 0.5 mg/L or 1 mg/L, whereas the proportion
of patients reaching this PK/PD target decreased progressively at
higher MICs.
Considering the targeted fT>MIC (75%), the vast majority of
patients (76%) achieved a satisfactory fT>MICwhen an MIC of 2 mg/L
was considered.
S. Corcione et al. / Journal of Global Antimicrobial Resistance 20 (2020) 22–27 27This proposal is also supported by a recently published
population PK analysis in septic shock patients where prolonged
or continuous infusion and increased dosages of meropenem
appeared to enhance therapeutic effectiveness, particularly in
patients with augmented renal clearance [14]. Moreover, pro-
longed infusion of meropenem appears to be associated with a
higher clinical improvement rate and a lower mortality in severe
infection [19]. According to data from a different setting of
critically ill patients, the current data support the idea that burn
patients may also benefit from prolonged infusion of a high dosage
of meropenem (2 g q8h), possibly with a loading dose, regardless of
augmented renal clearance [14,19,20].
Moreover, according to the need for better personalised
therapy, a more active approach with routine use of therapeutic
drug monitoring appears to be effective to reduce toxicity and to
improve efficacy, especially in burn patients.
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